Theravance Biopharma (TBPH) Change in Account Payables (2013 - 2026)
Theravance Biopharma's (TBPH) quarterly Change in Account Payables came in at -$1.5 million in Q1 2026, down 984.34% year-on-year from $166000.0 in Q1 2025, and down 513.52% on a QoQ basis from $355000.0 in Q4 2025.
Theravance Biopharma (TBPH) Change in Account Payables (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Change in Account Payables data on file, last reported at -$1.5 million in Q1 2026.
- On a quarterly basis, Change in Account Payables fell 984.34% year-over-year to -$1.5 million in Q1 2026; TTM through Mar 2026 was -$1.3 million, a 278.69% decrease from a year earlier, with the FY2025 full-year figure at $326000.0, down 56.53% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$1.5 million, down from $355000.0 in the prior quarter.
- Over the last five years, Change in Account Payables for TBPH reached as high as $2.2 million in Q3 2022 and fell as low as -$3.8 million in Q4 2022.
- Historically, Change in Account Payables has averaged -$117529.4 across 5 years, with a median of $166000.0 in 2025.
- On a YoY basis, Change in Account Payables climbed as much as 344.55% in 2025 and fell as far as 36550.0% in 2025.
- Year by year, Change in Account Payables stood at -$3.8 million in 2022, then surged by 90.75% to -$348000.0 in 2023, then soared by 326.44% to $788000.0 in 2024, then slumped by 54.95% to $355000.0 in 2025, then tumbled by 513.52% to -$1.5 million in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were -$1.5 million in Q1 2026, $355000.0 in Q4 2025, and $538000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - | -1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.47 Mn |
| Mar 31, 2026 | -1.47 Mn |
| Dec 31, 2025 | 355,000.00 |
| Dec 31, 2025 | 355,000.00 |
| Sep 30, 2025 | 538,000.00 |
| Sep 30, 2025 | 538,000.00 |
| Jun 30, 2025 | -733,000.00 |
| Jun 30, 2025 | -733,000.00 |
| Mar 31, 2025 | 166,000.00 |
| Mar 31, 2025 | 166,000.00 |
| Dec 31, 2024 | 788,000.00 |
| Dec 31, 2024 | 788,000.00 |
| Sep 30, 2024 | -220,000.00 |
| Sep 30, 2024 | -220,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | 184,000.00 |
| Mar 31, 2024 | 184,000.00 |
| Dec 31, 2023 | -348,000.00 |
| Dec 31, 2023 | -348,000.00 |